Clinical Trials–Making Good News Better

Written by: Steve Piccoli, Chief Science Officer Recent published results (AACR 2018 and NEJM) from the Merck KEYNOTE-189 trial in non-squamous non-small cell lung cancer (NSCLC) proved to be very exciting in the world of oncology. The study showed that patients...

Immunotherapy Making Strides at ASCO-SITC Immuno-Oncology Symposium

In late February, the American Society of Clinical Oncology (ASCO) partnered with the Society for Immunotherapy of Cancer (SITC) to host the first ASCO-SITC Clinical Immuno-Oncology Symposium, held in Orlando. We learned, along with 1000 other attendees, about the...

Response to FiercePharma Article

CLIENT: Pierian Biosciences DATE: February 17, 2017 PROJECT: PR – Blog post – Response to FiercePharma article Author: Robert Henry A recent FiercePharma article on the top 15 cancer drugs for 2022 predicts they will total nearly $90 billion in sales. That’s a...

PR – Op-Ed: Response to New Clinical Trials Requirements from HHS

Client: DiaTech Holdings/Pierian Biosciences, Inc. Date: September 21, 2016 Project: PR – Op-Ed: Response to New Clinical Trials Requirements from HHS Cancer deaths have declined substantially in the past decade. According to the National Cancer Institute, from 2003...